Testing the Efficacy of an eHealth Decision Support Tool to Help Latinx Cancer Patients Make Informed Decisions About Tumor Genomic Testing
Fox Chase Cancer Center
Summary
This is a randomized controlled trial designed to evaluate the efficacy of an electronic health decision support tool called Gene PilotLX to increase informed decision making regarding hereditary risk information from tumor genomic profiling (TGP) test among Latinx cancer patients recruited at four cancer centers.
Description
The use of multi-gene tumor genomic profiling (TGP) to examine a patient's tumor for targetable mutations is a cornerstone of personalized oncology. Providers are required to communicate TGP risks to patients and elicit patient preferences for managing information (i.e., "opt out" or have genetic counseling) because of the possibility of uncovering secondary hereditary cancer risks found on this test. Yet barriers exist to support optimal decision-making. Limited study of genetic links to cancer has been done with Latinx patients making them an important understudied group to target for geneti…
Eligibility
- Age range
- 18–80 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Self-identified Latinx patients who: 1. diagnosed with solid tumor cancers 2. speak/read English or Spanish; 3. can provide informed consent. Exclusion Criteria: Patients with hematologic/liquid cancers (leukemia, lymphoma, multiple myeloma, etc.)
Interventions
- OtherGene PilotLX
eHealth decision making tool regarding tumor genomic profiling
Locations (4)
- MD Anderson Cancer Center at CooperCamden, New Jersey
- Herbert Irving Comprehensive Cancer CenterNew York, New York
- Fox Chase Cancer CenterPhiladelphia, Pennsylvania
- Temple University HospitalPhiladelphia, Pennsylvania